Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Linhui Peng
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06041477CT.gov Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC | — | Recruiting | — | — | — |
NCT06172205CT.gov Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC | — | Recruiting | — | — | — |
NCT04962958CT.gov Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery | — | Unknown | — | — | — |
NCT05861505CT.gov COLLISION RELAPSE Trial | — | Recruiting | — | — | — |
NCT05515796CT.gov Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors | — | Completed | — | — | — |
NCT05353582CT.gov Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases | — | Unknown | — | — | — |
NCT05262452CT.gov Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer | — | Unknown | — | — | — |
NCT04447092CT.gov Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer | — | Unknown | — | — | — |
NCT03975049CT.gov Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT03210298CT.gov International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) | — | Unknown | — | — | — |
Show 1 more trialShow fewer
NCT01099449CT.gov Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chemotherapy-Induced Toxicity
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxaliplatin (this asset) | Linhui Peng | P3 | B · 63 |
| Palonosetron | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | A |
| Dexasone | Instituto do Cancer do Estado de São Paulo | P4 | A |
| Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| HR20013 | Fujian Shengdi Pharmaceutical Co., Ltd. | P3 | BB |
| Netupitant | Instituto Brasileiro de Controle do Cancer | P3 | BB |
| Docetaxel | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BB |
| Carboplatin | Endeavor Health | P3 | BB |
| Ondansetron | Dr Atul Sharma | P3 | BB |
+42 more in the Chemotherapy-Induced Toxicity cohort
Other indications for Oxaliplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 76 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
| Colorectal Neoplasm | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- PalonosetronSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityA
- DexasoneInstituto do Cancer do Estado de São PauloA
- Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]-Second Affiliated Hospital, School of Medicine, Zhejiang UniversityBBB
- HR20013Fujian Shengdi Pharmaceutical Co., Ltd.BB
- NetupitantInstituto Brasileiro de Controle do CancerBB
Citation
Floatz Terminal. Oxaliplatin in Chemotherapy-Induced Toxicity. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxaliplatin-chemotherapy-induced-toxicity
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →